Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season
Jonathan Pelletier, Sarah Rush, Eric D. Robinette, Danielle Maholtz, Michael T. Bigham, Michael L. Forbes, Steven L. Shein, Todd Karsies, Christopher M. Horvat
Abstract
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Topics & Concepts
MedicineAdministration (probate law)CohortEmergency medicinePediatricsCohort studyRespiratory systemVirusInternal medicineIncidence (geometry)Intensive care medicineRespiratory diseaseMEDLINEEpidemiologyVirologyRetrospective cohort studyPalivizumabRespiratory viral infections researchPneumonia and Respiratory InfectionsNeonatal Respiratory Health Research